On February 25, 2014, DARA BioScience, Inc. (DARA) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to KRN5500 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics. We see this as positive news for DARA, especially since we've been talking about this since late November 2012 when the application was first filed! We encourage investors to view our recent Seeking-Alpha article on KRN5500 to get a sense on just what gaining ODD status for the drug means.
But more important than gaining ODD status on KRN5500, and central to our thesis on the stock, is the potential for top-line acceleration and DARA's burgeoning specialty...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|